Dolutegravir contains Dolutegravir Sodium as its active component. It belongs to the class of antiretroviral medicines known as integrase strand-transfer inhibitors (INSTIs) and is used to treat human immunodeficiency virus type 1 (HIV-1) infection. The medication is supplied as a 50 mg oral pill and is available by prescription only in Hong Kong. Regulatory oversight is provided by the Hong Kong Department of Health in alignment with international standards such as those of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Dolutegravir blocks the HIV integrase enzyme, which is essential for the virus to insert its genetic material into the host cell’s DNA. By preventing this integration step, the drug stops the virus from replicating and reduces the amount of HIV (viral load) in the bloodstream.
Dolutegravir is approved in Hong Kong for the treatment of HIV-1 infection in the following scenarios:
Dolutegravir is typically prescribed as part of a combination antiretroviral therapy (cART) that includes two nucleoside reverse transcriptase inhibitors (NRTIs) such as abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine.
Current peer-reviewed evidence does not support routine off-label uses of Dolutegravir in Hong Kong. Any consideration of unapproved indications must be undertaken under specialist supervision, with a clear discussion of risks and benefits.
This article provides educational information about Dolutegravir and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Dolutegravir has a higher barrier to resistance and can be used as a once-daily, single-tablet regimen without the need for boosting agents, unlike some earlier INSTIs that require twice-daily dosing.
Iron supplements may lower Dolutegravir absorption. Separate the doses by at least 6 hours to avoid reduced efficacy.
Dolutegravir itself does not treat hepatitis B, but it can be combined with NRTIs that have activity against hepatitis B (e.g., tenofovir). Liver function should be monitored regularly.
Dolutegravir does not interfere with standard urine or serum pregnancy tests. However, women of child-bearing potential should discuss contraception and the modest risk of neural tube defects with their provider.
Report any rash to a healthcare professional promptly. Mild rashes may resolve without discontinuation, but severe or spreading rashes require urgent evaluation for possible hypersensitivity.
Yes. Carry the medication in its original packaging, with a copy of the prescription or a doctor’s note, to ease customs inspections. Keep the pills in a temperature-controlled environment if traveling to extreme climates.
Dairy contains calcium, which can bind Dolutegravir and reduce its absorption. If you consume calcium-rich foods or supplements, maintain the recommended separation interval (≥ 2 hours before or ≥ 6 hours after taking the pill).
Dolutegravir is not primarily cleared by the kidneys, so routine renal monitoring is not required unless the patient has pre-existing kidney disease or is on other nephrotoxic drugs.
Both are INSTIs with high resistance barriers. Bictegravir is co-formulated with two NRTIs in a single tablet, while Dolutegravir is often paired with separate NRTIs. Choice depends on individual patient factors and physician preference.
A single double dose is unlikely to cause serious toxicity, but you should contact a healthcare professional for guidance and avoid repeating the mistake.
